SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-054737
Filing Date
2018-10-10
Accepted
2018-10-10 19:31:27
Documents
2
Period of Report
2018-10-10

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3375
2 POA DOCUMENT poa.txt EX-24.3_813289 3049
  Complete submission text file 0001209191-18-054737.txt   7801
Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
WITTE OWEN N. (Reporting) CIK: 0001700969 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38693 | Film No.: 181117061

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)